Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Goff

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Substance Use & Misuse|February 4, 2017
Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency SettingMarc W Manseau, Amit Rajparia, Adriana Joseph, et al.
Biological Psychiatry|October 6, 2006
Fronto-hippocampal function during temporal context monitoring in schizophreniaAnthony P Weiss, Donald Goff, Daniel L Schacter, et al.
Schizophrenia Bulletin|December 2, 2005
Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI studyKang Sim, Iain DeWitt, Tali Ditman, et al.
Schizophrenia Research|March 2, 2010
Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophreniaXiaoduo Fan, Emily Y Liu, Oliver Freudenreich, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Human Brain Mapping|March 1, 2020
Parietal memory network and default mode network in first-episode drug-naïve schizophrenia: Associations with auditory hallucinationQian Guo, Yang Hu, Botao Zeng, et al.
JAMA Psychiatry|March 28, 2019
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical TrialHannah E Brown, Oliver Freudenreich, Xiaoduo Fan, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
Brain Imaging and Behavior|January 29, 2019
Aberrant resting-state functional connectivity of salience network in first-episode schizophreniaHuan Huang, Zeng Botao, Yuchao Jiang, et al.
Schizophrenia Research|January 15, 2021
Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophreniaFaith Dickerson, Emily Katsafanas, Andrea Origoni, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Substance Use & Misuse|February 4, 2017
Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency SettingMarc W Manseau, Amit Rajparia, Adriana Joseph, et al.
Biological Psychiatry|October 6, 2006
Fronto-hippocampal function during temporal context monitoring in schizophreniaAnthony P Weiss, Donald Goff, Daniel L Schacter, et al.
Schizophrenia Bulletin|December 2, 2005
Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI studyKang Sim, Iain DeWitt, Tali Ditman, et al.
Schizophrenia Research|March 2, 2010
Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophreniaXiaoduo Fan, Emily Y Liu, Oliver Freudenreich, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Human Brain Mapping|March 1, 2020
Parietal memory network and default mode network in first-episode drug-naïve schizophrenia: Associations with auditory hallucinationQian Guo, Yang Hu, Botao Zeng, et al.
JAMA Psychiatry|March 28, 2019
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical TrialHannah E Brown, Oliver Freudenreich, Xiaoduo Fan, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
Brain Imaging and Behavior|January 29, 2019
Aberrant resting-state functional connectivity of salience network in first-episode schizophreniaHuan Huang, Zeng Botao, Yuchao Jiang, et al.
Schizophrenia Research|January 15, 2021
Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophreniaFaith Dickerson, Emily Katsafanas, Andrea Origoni, et al.
Pageof 4